AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

被引:269
作者
Handelsman, Yehuda [1 ,2 ]
Henry, Robert R. [3 ,4 ]
Bloomgarden, Zachary T. [5 ]
Dagogo-Jack, Sam [6 ]
DeFronzo, Ralph A. [7 ]
Einhorn, Daniel [8 ,9 ,10 ,11 ,12 ]
Ferrannini, Ele [13 ]
Fonseca, Vivian A. [14 ,15 ,16 ]
Garber, Alan J. [17 ,18 ,19 ]
Grunberger, George [20 ,21 ,22 ,23 ,24 ]
LeRoith, Derek [25 ]
Umpierrez, Guillermo E. [26 ,27 ]
Weir, Matthew R. [28 ,29 ]
机构
[1] Metab Inst Amer, Tarzana, CA USA
[2] Amer Coll Endocrinol, Tarzana, CA USA
[3] Univ Calif San Diego, Med, San Diego, CA 92103 USA
[4] VA San Diego Healthcare Syst, Sect Diabet Endocrinol & Metab, San Diego, CA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Univ Tennessee, Hlth Sci Ctr, Div Endocrinol Diabet & Metab, Memphis, TN USA
[7] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA
[8] Amer Coll Endocrinol, La Jolla, CA USA
[9] Amer Assoc Clin Endocrinologists, La Jolla, CA USA
[10] Scripps Whittier Diabet Inst, La Jolla, CA USA
[11] UCSD, Med, La Jolla, CA USA
[12] Diabet & Endocrine Associates, Journal Diabet, La Jolla, CA USA
[13] CNR, Inst Clin Physiol, Internal Med, Via Savi 8, I-56100 Pisa, Italy
[14] Tulane Univ, Hlth Sci Ctr, Med & Pharmacol, New Orleans, LA 70118 USA
[15] Tulane Univ, Hlth Sci Ctr, Diabet, New Orleans, LA 70118 USA
[16] Tulane Univ, Hlth Sci Ctr, Endocrinol Sect, New Orleans, LA 70118 USA
[17] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[18] Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA
[19] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[20] Amer Assoc Clin Endocrinologists, Bloomfield Hills, MI USA
[21] Grunberger Diabet Inst, Bloomfield Hills, MI USA
[22] Wayne State Univ, Sch Med, Internal Med & Mol Med & Genet, Detroit, MI USA
[23] Oakland Univ, William Beaumont Sch Med, Internal Med, Rochester, MI 48063 USA
[24] Charles Univ Prague, Fac Med 1, Internal Med, Prague, Czech Republic
[25] Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Res, New York, NY USA
[26] Emory Univ, Sch Med, Med, Atlanta, GA USA
[27] Grady Hlth Syst, Endocrinol Sect, Atlanta, GA USA
[28] Univ Maryland, Sch Med, Div Nephrol, Baltimore, MD 21201 USA
[29] Univ Maryland, Sch Med, Med, Baltimore, MD 21201 USA
关键词
COTRANSPORTER; 2; INHIBITOR; ADJUNCT THERAPY; DOUBLE-BLIND; TYPE-1; INSULIN; GLUCOSE; SAFETY; DAPAGLIFLOZIN; LIPOLYSIS; EFFICACY;
D O I
10.4158/EP161292.PS
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
引用
收藏
页码:753 / 762
页数:10
相关论文
共 49 条
[41]   DIABETIC-KETOACIDOSIS IN DENMARK - EPIDEMIOLOGY, INCIDENCE RATES, PRECIPITATING FACTORS AND MORTALITY-RATES [J].
SNORGAARD, O ;
ESKILDSEN, PC ;
VADSTRUP, S ;
NERUP, J .
JOURNAL OF INTERNAL MEDICINE, 1989, 226 (04) :223-228
[42]   Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment [J].
Storgaard, Heidi ;
Bagger, Jonatan I. ;
Knop, Filip K. ;
Vilsboll, Tina ;
Rungby, Jorgen .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 118 (02) :168-170
[43]   SGLT inhibitors in management of diabetes [J].
Tahrani, Abd A. ;
Barnett, Anthony H. ;
Bailey, Clifford J. .
LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (02) :140-151
[44]  
Tamez HE, 2015, J DIABETES METAB DIS, V14, DOI 10.1186/s40200-015-0210-x
[45]   Ketoacidosis occurs in both Type 1 and Type 2 diabetes - a population-based study from Northern Sweden [J].
Wang, Z. H. ;
Kihl-Selstam, E. ;
Eriksson, J. W. .
DIABETIC MEDICINE, 2008, 25 (07) :867-870
[46]   EFFECT OF EPINEPHRINE AND SOMATOSTATIN-INDUCED INSULIN DEFICIENCY ON KETONE-BODY KINETICS AND LIPOLYSIS IN MAN [J].
WEISS, M ;
KELLER, U ;
STAUFFACHER, W .
DIABETES, 1984, 33 (08) :738-744
[47]   Active sugar transport in health and disease [J].
Wright, E. M. ;
Hirayama, B. A. ;
Loo, D. F. .
JOURNAL OF INTERNAL MEDICINE, 2007, 261 (01) :32-43
[48]   SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats [J].
Yokono, Masanori ;
Takasu, Toshiyuki ;
Hayashizaki, Yuka ;
Mitsuoka, Keisuke ;
Kihara, Rumi ;
Muramatsu, Yuko ;
Miyoshi, Sousuke ;
Tahara, Atsuo ;
Kurosaki, Eiji ;
Li, Qun ;
Tomiyama, Hiroshi ;
Sasamata, Masao ;
Shibasaki, Masayuki ;
Uchiyama, Yasuo .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 727 :66-74
[49]   Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].
Zinman, Bernard ;
Wanner, Christoph ;
Lachin, John M. ;
Fitchett, David ;
Bluhmki, Erich ;
Hantel, Stefan ;
Mattheus, Michaela ;
Devins, Theresa ;
Johansen, Odd Erik ;
Woerle, Hans J. ;
Broedl, Uli C. ;
Inzucchi, Silvio E. ;
Aizenberg, D. ;
Ulla, M. ;
Waitman, J. ;
De Loredo, L. ;
Farias, J. ;
Fideleff, H. ;
Lagrutta, M. ;
Maldonado, N. ;
Colombo, H. ;
Ferre Pacora, F. ;
Wasserman, A. ;
Maffei, L. ;
Lehman, R. ;
Selvanayagam, J. ;
d'Emden, M. ;
Fasching, P. ;
Paulweber, B. ;
Toplak, H. ;
Luger, A. ;
Drexel, H. ;
Prager, R. ;
Schnack, C. ;
Schernthaner, G. ;
Fliesser-Goerzer, E. ;
Kaser, S. ;
Scheen, A. ;
Van Gaal, L. ;
Hollanders, G. ;
Kockaerts, Y. ;
Capiau, L. ;
Chachati, A. ;
Persu, A. ;
Hermans, M. ;
Vantroyen, D. ;
Vercammen, C. ;
Van de Borne, P. ;
Mathieu, C. ;
Benhalima, K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128